

4 May 2026

## Botanix appoints Chief Operating Officer

**Philadelphia PA and Phoenix AZ, 4 May 2026:** Commercial dermatology company, Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, “Botanix” or “the Company”), announces the promotion of Paul Seaback to Chief Operating Officer (COO). In his new role, he will oversee the Company’s day-to-day operations, drive strategic initiatives, and support continued growth and efficiencies across key business areas.

He is an accomplished biopharmaceutical executive with over three decades of industry experience, including senior leadership roles at leading innovator, generic and specialty pharmaceutical companies, and organisations scaling for growth. Mr Seaback joined Botanix as Chief Technical Officer in November 2024, with a span of control that included CMC/Supply, Quality, Regulatory, Pharmacovigilance, Medical Affairs, and Tech Services. He has contributed significant operational expertise to Botanix.

Mr Seaback’s career extends from drug substance and drug product site leadership roles to corporate-level oversight of end-to-end supply functions and business operations, consistently driving growth. Before joining Botanix, Mr Seaback was Chief Technical Officer at Dermavant Sciences (a Roivant company) until its acquisition by Organon, where he developed the global CMC and technical organisation from a clinical stage into a commercial entity. Prior to Dermavant, Mr Seaback was the VP of Operations & Supply until its acquisition by Roche. He has also held global leadership roles at Gilead, Medicis, Hospira, Mayne and Novartis (Sandoz), supporting the commercialisation of leading products including Sovaldi/Harvoni, Vtama, Solodyn, Truvada and Vemlidy.

“Paul Seaback is a dynamic and results-driven leader who brings deep operational expertise and a strong vision for the future,” said *Dr Howie McKibbon, Chief Executive Officer of Botanix*. “We are pleased to recognize his contributions with a well-deserved promotion to Chief Operating Officer as we continue to expand our capabilities and deliver value to our customers and shareholders.”

In his new role, Mr Seaback will focus on optimising operational performance, enhancing cross-functional collaboration, and implementing scalable processes to support the company’s long-term strategy.

“I’m thrilled to assume this role at such an exciting time for the Company,” said *Mr Seaback*. “I look forward to working with the talented and dedicated team to build on the company’s strong foundation and help drive the next phase of growth.”

Release authorised by

**Vince Ippolito**

Executive Chairman

## About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has received FDA approval for Sofdra, its product for the treatment of primary axillary hyperhidrosis. Sofdra is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel, safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more please visit: <http://www.botanixpharma.com/>

### For more information, please contact:

General enquiries  
Corporate Communications  
Botanix Pharmaceuticals  
P: +61 8 6285 0083  
[info@botanixpharma.com](mailto:info@botanixpharma.com)

Investor enquiries  
Hannah Howlett  
P: +61 4 5064 8064  
[investors@botanixpharma.com](mailto:investors@botanixpharma.com)

Media enquiries  
Haley Chartres  
H^CK  
P: +61 423 139 163  
[haley@hck.digital](mailto:haley@hck.digital)

## Cautionary Note on Forward-Looking Statements

Forward-looking statements can generally be identified by the use of forward-looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target” “outlook”, “guidance” and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company’s strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan, the outcome and effects of *Sofdra* and the market for *Sofdra*. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. The forward-looking statements contained in this Presentation are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Investors should consider the forward-looking statements contained in this Presentation in light of those disclosures and not place undue reliance on such statements. Except as required by law or regulation, Botanix undertakes no obligation to update forward-looking statements.